Vaxcyte Inc
$ 60.81
0.43%
22 Apr - close price
- Market Cap 8,829,993,000 USD
- Current Price $ 60.81
- High / Low $ 61.82 / 60.27
- Stock P/E N/A
- Book Value 20.49
- EPS -5.63
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.18 %
- ROE -0.26 %
- 52 Week High 65.00
- 52 Week Low 28.09
About
Vaxcyte, Inc., a pre-clinical biotech vaccine company, develops novel vaccines to prevent or treat infectious diseases globally. The company is headquartered in Foster City, California.
Analyst Target Price
$109.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-02 | 2025-11-04 | 2025-08-06 | 2025-05-06 | 2025-02-25 | 2024-11-04 | 2024-08-06 | 2024-05-08 | 2024-02-27 | 2023-11-06 | 2023-08-08 | 2023-05-08 |
| Reported EPS | -1.8 | -1.56 | -1.22 | -1.04 | -1.0176 | -0.83 | -1.1 | -0.85 | -1.82 | -0.91 | -0.7 | -0.7 |
| Estimated EPS | -1.47 | -1.24 | -1.17 | -0.975 | -0.992 | -1.13 | -0.98 | -1.17 | -1.07 | -0.84 | -0.74 | -0.83 |
| Surprise | -0.33 | -0.32 | -0.05 | -0.065 | -0.0256 | 0.3 | -0.12 | 0.32 | -0.75 | -0.07 | 0.04 | 0.13 |
| Surprise Percentage | -22.449% | -25.8065% | -4.2735% | -6.6667% | -2.5806% | 26.5487% | -12.2449% | 27.3504% | -70.0935% | -8.3333% | 5.4054% | 15.6627% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.86 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PCVX
2026-04-23 20:09:25
This article announces an ARS SEC filing by Vaxcyte, Inc. (PCVX) on April 23, 2026. The filing has a low impact and neutral sentiment. The article also provides a company overview, recent news, and other SEC filings for Vaxcyte, Inc.
2026-04-23 03:08:49
This article identifies five top-performing US stocks hitting 52-week highs, highlighting strong investment opportunities. It features Vaxcyte Inc. (NASDAQ:PCVX), detailing its Phase 3 clinical trials for a pneumococcal vaccine and its financial stability. The piece also includes a section on the projected $250 trillion AI market, promoting a report on an undervalued AI company.
2026-04-16 12:09:43
Insiders at Vaxcyte (NASDAQ:PCVX) recently sold US$1.0 million worth of company stock over the last year, suggesting potential weakness. While insider selling doesn't always signal trouble, it can be a red flag when combined with a lack of significant insider buying. In Vaxcyte's case, the largest individual sale was by the CEO, although this represents a small portion of their holdings.
2026-04-15 13:41:16
Needham has reiterated its Buy rating for Vaxcyte (PCVX.US) and maintained its price target at $110. This indicates a continued positive outlook from the firm regarding Vaxcyte's stock performance.
2026-04-12 08:39:14
This article provides an overview of Vaxcyte Inc.'s (PCVX) financial performance, focusing on its profitability metrics and market positioning. It highlights the company's gross, operating, and net margins, as well as its Return on Equity. The article also includes a comparison of PCVX's efficiency against competitors TECH and ARWR, noting its market capitalization of $8.76 billion.
2026-04-10 07:09:49
Vaxcyte's Chief Accounting Officer, Elvia Cowan, sold 3,000 shares of company stock for $180,000 on April 7, 2026. This transaction reduced her ownership by 9.38% and was conducted under a pre-arranged Rule 10b5-1 trading plan. The sale provides insight into management's view of the company's valuation as Vaxcyte continues to develop preventive vaccines.
